Goldenberg is among doctors who believe all Cox-2 inhibitors carry some cardiovascular risk.
He called for a thorough revamping of the agency's process for reviewing drug safety.
It said possible changes to marketing authorizations could include labeling throughout the European Union.
An analyst for Lehman Brothers, said that the recent slide in Merck's share price A 7,111-patient trial was presented last week at the American College of Rheumatology's annual meeting in San Antonio.
It found that dropout rates due to stomach problems were more than double in the patients taking diclofenac than in those taking Arcoxia.
